Foghorn's stock drops 23% after FDA puts partial hold on clinical trial

Shares of Foghorn Therapeutics Inc. /zigman2/quotes/222085286/composite FHTX +2.79% were down 23.7% in premarket trading on Friday, the day after the company said U.S. regulators had placed a partial clinical hold on a Phase 1 clinical trial assessing an experimental therapy for relapsed and/or refractory acute myelogenous leukemia. The Food and Drug Administration has asked for a review of the safety database, as well as information about risk mitigation and clinical activity across doses. Foghorn's stock has declined 49.3% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +1.06% is down 18.1%.

/zigman2/quotes/222085286/composite

Add to watchlist FHTX

Foghorn Therapeutics Inc.

US : U.S.: Nasdaq

$ 13.98

+0.38 +2.79%

Volume: 46,278

July 1, 2022 4:00p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$579.72 million

Rev. per Employee

$41,622

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

3,825.33

+39.95 +1.06%

Volume: 2.20B

July 1, 2022 5:45p